#HVO hVIVO – POSITIVE RESULTS FROM CLIENT PHASE 2B FIELD STUDY June 30, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO recruited participants and performed the virology and immunology laboratory services for the study   hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates Cidara Therapeutics (Cidara: Nasdaq CDTX) on the positive topline results from their Phase 2bfield study, for which hVIVO recruited participants and performed the virology and immunology laboratory services.  The study was to determine the efficacy of Cidara’s drug-Fc conjugate, CD388, which is…

Continue reading